VC
IRD

Voss Capital’s Opus Genetics IRD Stock Holding History

Voss Capital’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-441,891
Closed -$888K – 71
2025
Q4 		$888K Sell
441,891
-120,486
-21% -$245K 0.04% 50
2025
Q3 		$928K Buy
562,377
+21,218
+4% +$26.4K 0.05% 51
2025
Q2 		$510K Buy
541,159
+391,159
+261% +$362K 0.04% 52
2025
Q1 		$147K Sell
150,000
-40,958
-21% -$45.8K 0.01% 56
2024
Q4 		$227K Buy
+190,958
New +$219K 0.02% 44

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Voss Capital's IRD Position: Q1 2026 in Review

Voss Capital sold out of Opus Genetics (IRD) in Q1 2026, closing a stake of 441,891 shares — an estimated $888K sold.

Voss Capital first reported a position in IRD in Q4 2024 and held it in 5 quarters. The position peaked at $928K in Q3 2025. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Voss Capital reported no remaining Opus Genetics position as of Q1 2026 after selling out during the quarter.
  • Voss Capital sold 441,891 Opus Genetics shares in Q1 2026, an estimated $888K.
  • Voss Capital first reported a position in Opus Genetics in Q4 2024 and held it in 5 quarters.
  • Voss Capital's Opus Genetics position peaked at $928K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Voss Capital's 13F filing for Q1 2026, filed 15 May 2026.